Brokers Offer Predictions for FBRX Q4 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Research analysts at Brookline Capital Markets issued their Q4 2026 earnings per share estimates for shares of Forte Biosciences in a research note issued to investors on Wednesday, May 13th. Brookline Capital Markets analyst K. Raja anticipates that the company will earn ($0.90) per share for the quarter. The consensus estimate for Forte Biosciences’ current full-year earnings is ($4.63) per share.

Forte Biosciences (NASDAQ:FBRX) last released its earnings results on Monday, May 11th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.08).

A number of other research firms also recently issued reports on FBRX. Wall Street Zen downgraded shares of Forte Biosciences from a “sell” rating to a “strong sell” rating in a research report on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of Forte Biosciences in a report on Friday, March 27th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Forte Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Forte Biosciences Stock Performance

FBRX stock opened at $24.66 on Thursday. The stock has a market cap of $342.53 million, a P/E ratio of -5.31 and a beta of 3.01. The firm has a 50 day simple moving average of $27.84 and a 200 day simple moving average of $25.44. Forte Biosciences has a 52 week low of $6.70 and a 52 week high of $35.80.

Hedge Funds Weigh In On Forte Biosciences

A number of hedge funds have recently added to or reduced their stakes in the company. Candriam S.C.A. bought a new position in Forte Biosciences during the first quarter valued at approximately $2,196,000. Quadrature Capital Ltd bought a new stake in Forte Biosciences in the fourth quarter worth approximately $479,000. Millennium Management LLC increased its stake in shares of Forte Biosciences by 105.9% during the 4th quarter. Millennium Management LLC now owns 246,685 shares of the company’s stock worth $6,727,000 after purchasing an additional 126,873 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Forte Biosciences by 1.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,425,785 shares of the company’s stock valued at $39,159,000 after purchasing an additional 21,943 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Forte Biosciences in the 4th quarter valued at $1,091,000. Institutional investors and hedge funds own 77.63% of the company’s stock.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.